arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR
download Export Data

Adagene Inc.

ADAG
$4.15 ▲ +0.03 (+0.73%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
7 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Adagene Inc. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book 7.0x
FCF Yield —
Debt / Equity 0.03
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Long-Term Debt Long-term obligations
$1.14M
↑ +172.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
17
Financial Health ↑
54
Cash Quality ↑
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 9 quarters